

Françoise Kraeber-Bodéré

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4031867/publications.pdf>

Version: 2024-02-01

192
papers

5,947
citations

66343

42
h-index

95266

68
g-index

212
all docs

212
docs citations

212
times ranked

6277
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Pilot study with [¹⁸ F]DPA-714 PET-CT to explore tumor-associated-macrophages in triple negative breast cancer.. Journal of Clinical Oncology, 2022, 40, e12557-e12557. | 1.6 | 0 |
| 2 | Standardization of ¹⁸ F-FDG PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 116-125. | 1.6 | 85 |
| 3 | Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1005-1015. | 6.4 | 35 |
| 4 | Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood, 2021, 137, 2307-2320. | 1.4 | 48 |
| 5 | Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study. Journal of Nuclear Medicine, 2021, 62, 1221-1227. | 5.0 | 12 |
| 6 | Radioimmunotherapy for Brain Metastases: The Potential for Inflammation as a Target of Choice. Frontiers in Oncology, 2021, 11, 714514. | 2.8 | 5 |
| 7 | Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib. European Thyroid Journal, 2021, 10, 1-6. | 2.4 | 2 |
| 8 | Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis. International Journal of Computer Assisted Radiology and Surgery, 2020, 15, 129-139. | 2.8 | 22 |
| 9 | Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. Haematologica, 2020, 105, e33-e36. | 3.5 | 31 |
| 10 | Good clinical practice recommendations for the use of PET/CT in oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 28-50. | 6.4 | 85 |
| 11 | Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease. Cancers, 2020, 12, 2721. | 3.7 | 11 |
| 12 | Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases. Biomedicines, 2020, 8, 548. | 3.2 | 8 |
| 13 | Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. International Journal of Molecular Sciences, 2020, 21, 5406. | 4.1 | 13 |
| 14 | Usefulness of FDG-PET/CT-Based Radiomics for the Characterization and Genetic Orientation of Pheochromocytomas Before Surgery. Cancers, 2020, 12, 2424. | 3.7 | 13 |
| 15 | RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. EJHaem, 2020, 1, 318-322. | 1.0 | 2 |
| 16 | Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. Cancers, 2020, 12, 2532. | 3.7 | 17 |
| 17 | ImmunoPET in Multiple Myeloma—What? So What? Now What?. Cancers, 2020, 12, 1467. | 3.7 | 8 |
| 18 | Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer. Cancers, 2020, 12, 1512. | 3.7 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?. <i>Cancers</i> , 2020, 12, 1384. | 3.7 | 6 |
| 20 | Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1205-1211. | 5.0 | 22 |
| 21 | Editorial: Nuclear Medicine in the Context of Personalized Medicine. <i>Frontiers in Medicine</i> , 2020, 7, 252. | 2.6 | 2 |
| 22 | Cell Tracking in Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2020, 7, 34. | 2.6 | 52 |
| 23 | Imaging of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Cancers</i> , 2020, 12, 486. | 3.7 | 8 |
| 24 | IntÃ©rÃ©t pronostique et prÃ©dictif de la TEP-TDM au 18F-FDG au bilan initial des mÃ©lanomes de stade IIIB-C-D et IV avant traitement par anti-PD-1. <i>Medecine Nucleaire</i> , 2020, 44, 65-71. | 0.2 | 0 |
| 25 | Reply to E. Laffon <i>et al</i> ... <i>Haematologica</i> , 2020, 105, e42-e42. | 3.5 | 0 |
| 26 | Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study. <i>Blood</i> , 2020, 136, 26-26. | 1.4 | 0 |
| 27 | Preliminary results of a ⁶⁸ Gaâ€“PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decisionâ€“making. <i>Prostate</i> , 2019, 79, 1514-1522. | 2.3 | 25 |
| 28 | Potential for Nuclear Medicine Therapy for Glioblastoma Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 772. | 3.5 | 31 |
| 29 | EP-1936 PET/CT Radiomics predict local recurrence in patients treated with SBRT for early-stage NSCLC. <i>Radiotherapy and Oncology</i> , 2019, 133, S1054. | 0.6 | 0 |
| 30 | XEMIS2: A liquid xenon Compton camera to image small animals. , 2019, , . | | 3 |
| 31 | Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. <i>Cancers</i> , 2019, 11, 1282. | 3.7 | 43 |
| 32 | Recommandations et rÃ©fÃ©rentiels. <i>Medecine Nucleaire</i> , 2019, 43, 1-4. | 0.2 | 0 |
| 33 | Radioimmunotherapy of Lymphomas. , 2019, , 113-121. | | 3 |
| 34 | Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches. <i>Frontiers in Medicine</i> , 2019, 6, 124. | 2.6 | 20 |
| 35 | What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2564. | 4.1 | 22 |
| 36 | 68Ga-PSMA PET/CT Urachus Metastases in Recurrent Prostate Cancer With Very Low PSA Level. <i>Clinical Nuclear Medicine</i> , 2019, 44, 40-41. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | [18F]-Fludarabine for Hematological Malignancies. <i>Frontiers in Medicine</i> , 2019, 6, 77. | 2.6 | 9 |
| 38 | Mild sporadic primary hyperparathyroidism: high rate of multiglandular disease is associated with lower surgical cure rate. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 431-438. | 1.9 | 23 |
| 39 | Interest of FDG-PET in the Management of Mantle Cell Lymphoma. <i>Frontiers in Medicine</i> , 2019, 6, 70. | 2.6 | 13 |
| 40 | Interest of Pet Imaging in Multiple Myeloma. <i>Frontiers in Medicine</i> , 2019, 6, 69. | 2.6 | 34 |
| 41 | 18F-FDG PET/CT in multiple myeloma: critical insights and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1048-1050. | 6.4 | 1 |
| 42 | 18F-FDOPA PET Compared With 123I-Metaiodobenzylguanidine Scintigraphy and 18F-FDG PET in Secreting Sporadic Pheochromocytoma. <i>Clinical Nuclear Medicine</i> , 2019, 44, 738-740. | 1.3 | 5 |
| 43 | Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 906-911. | 2.0 | 6 |
| 44 | 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. <i>Prostate</i> , 2019, 79, 454-461. | 2.3 | 14 |
| 45 | Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 222-225. | 1.3 | 11 |
| 46 | Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study. <i>Blood</i> , 2019, 134, 692-692. | 1.4 | 42 |
| 47 | ¹⁸ F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1380-1385. | 5.0 | 15 |
| 48 | XEMIS2: A liquid xenon detector for small animal medical imaging. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2018, 912, 329-332. | 1.6 | 12 |
| 49 | Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know. <i>Journal of Nuclear Medicine</i> , 2018, 59, 714-715. | 5.0 | 1 |
| 50 | Alphatherapy, the new impetus to targeted radionuclide therapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1362-1363. | 6.4 | 1 |
| 51 | Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. <i>Oncotarget</i> , 2018, 9, 9061-9072. | 1.8 | 29 |
| 52 | Isolation of <i>Coxiella burnetii</i> from an acromioclavicular infection with low serological titres. <i>International Journal of Infectious Diseases</i> , 2018, 73, 27-29. | 3.3 | 6 |
| 53 | Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of $\hat{\rho}$ SUVmax in the FDG-Avid Patients of the IMAJEM Study. <i>Clinical Cancer Research</i> , 2018, 24, 5219-5224. | 7.0 | 24 |
| 54 | Prospects for Enhancing Efficacy of Radioimmunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 139-153. | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Gravity assisted recovery of liquid xenon at large mass flow rates. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2018, 893, 10-14. | 1.6 | 6 |
| 56 | Sensitivity of pretargeted immunoPET using ⁶⁸ Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with ¹⁸ F-FDG PET-CT. Oncotarget, 2018, 9, 27502-27513. | 1.8 | 12 |
| 57 | Report of the 6th International Workshop on PET in lymphoma. Leukemia and Lymphoma, 2017, 58, 2298-2303. | 1.3 | 21 |
| 58 | Radioimmunoconjugates for treating cancer: recent advances and current opportunities. Expert Opinion on Biological Therapy, 2017, 17, 813-819. | 3.1 | 27 |
| 59 | Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine". European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1559-1574. | 6.4 | 19 |
| 60 | Consolidation anti-CD22 fractionated radioimmunotherapy with ⁹⁰ Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematology, 2017, 4, e35-e45. | 4.6 | 33 |
| 61 | Pretargeting for imaging and therapy in oncological nuclear medicine. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 6. | 3.9 | 41 |
| 62 | Immuno-PET for Clinical Theranostic Approaches. International Journal of Molecular Sciences, 2017, 18, 57. | 4.1 | 50 |
| 63 | PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. International Journal of Molecular Sciences, 2017, 18, 445. | 4.1 | 23 |
| 64 | Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. Journal of Clinical Oncology, 2017, 35, 2911-2918. | 1.6 | 247 |
| 65 | Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. PLoS ONE, 2017, 12, e0183841. | 2.5 | 22 |
| 66 | Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors. Oncotarget, 2017, 8, 77050-77060. | 1.8 | 13 |
| 67 | ³ γ Medical Imaging with a Liquid Xenon Compton Camera and ⁴⁴ Sc Radionuclide. Acta Physica Polonica B, 2017, 48, 1661. | 0.8 | 8 |
| 68 | Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?. Current Cancer Therapy Reviews, 2016, 12, 54-65. | 0.3 | 3 |
| 69 | ImmunoPET to help stratify patients for targeted therapies and to improve drug development. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2166-2168. | 6.4 | 23 |
| 70 | Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸ Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. Journal of Nuclear Medicine, 2016, 57, 1505-1511. | 5.0 | 61 |
| 71 | Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response. Critical Reviews in Oncology/Hematology, 2016, 107, 182-189. | 4.4 | 6 |
| 72 | Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1849-1856. | 6.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Radioimmunotherapy for Treatment of Acute Leukemia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 135-146. | 4.6 | 31 |
| 74 | Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 329-331. | 5.0 | 15 |
| 75 | Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology. <i>Frontiers in Medicine</i> , 2016, 3, 74. | 2.6 | 3 |
| 76 | Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials. <i>PLoS ONE</i> , 2016, 11, e0159984. | 2.5 | 61 |
| 77 | Sodium 18F-sodium fluoride PET failed to predict responses to TNF α antagonist therapy in 31 patients with possible spondyloarthritis not meeting ASAS criteria. <i>Joint Bone Spine</i> , 2015, 82, 411-416. | 1.6 | 10 |
| 78 | Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up. <i>Frontiers in Medicine</i> , 2015, 2, 46. | 2.6 | 16 |
| 79 | Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with 18F-Choline PET/CT in Prostate Cancer. <i>Frontiers in Medicine</i> , 2015, 2, 67. | 2.6 | 6 |
| 80 | Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. <i>Frontiers in Medicine</i> , 2015, 2, 84. | 2.6 | 29 |
| 81 | Prognostic value of metabolic parameters and clinical impact of 18F-fluorocholine PET/CT in biochemical recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1784-1793. | 6.4 | 32 |
| 82 | A pretargeting system for tumor PET imaging and radioimmunotherapy. <i>Frontiers in Pharmacology</i> , 2015, 6, 54. | 3.5 | 41 |
| 83 | Assessment of a fully 3D Monte Carlo reconstruction method for preclinical PET with iodine-124. <i>Physics in Medicine and Biology</i> , 2015, 60, 2475-2491. | 3.0 | 4 |
| 84 | Tumor Immunotargeting Using Innovative Radionuclides. <i>International Journal of Molecular Sciences</i> , 2015, 16, 3932-3954. | 4.1 | 51 |
| 85 | 90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. <i>Lancet Haematology</i> , 2015, 2, e108-e117. | 4.6 | 36 |
| 86 | Management of thyroid nodules incidentally discovered on MIBI scanning for primary hyperparathyroidism. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 313-318. | 1.9 | 15 |
| 87 | XEMIS: A liquid xenon detector for medical imaging. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2015, 787, 89-93. | 1.6 | 20 |
| 88 | Impact of Functional and/or Phenotypic PET Imaging on the Determination of Clinical Target Volumes of Vertebral Metastases Before Stereotactic Body Radiation Therapy Compared to MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, S82-S83. | 0.8 | 0 |
| 89 | Abstract P5-01-01: Pretargeted immuno-PET with an anti-carcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and a68Ca-labeled hapten-peptide compared to conventional imaging and FDG-PET in metastatic breast cancer patients (BC): First results. , 2015, , . | | 1 |
| 90 | Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2015, 126, 335-335. | 1.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015, 126, 395-395. | 1.4 | 20 |
| 92 | Improvement in imaging of metastatic breast cancer (BC) with a novel pretargeted immuno-PET targeting CEA: First clinical results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11059-11059. | 1.6 | 0 |
| 93 | Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams -075. <i>Blood</i> , 2015, 126, 3920-3920. | 1.4 | 0 |
| 94 | Challenges in Nuclear Medicine: Innovative Theranostic Tools for Personalized Medicine. <i>Frontiers in Medicine</i> , 2014, 1, 16. | 2.6 | 10 |
| 95 | 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study. <i>Bone Marrow Transplantation</i> , 2014, 49, 131-137. | 2.4 | 30 |
| 96 | Clinical NECR in 18F-FDG PET scans: optimization of injected activity and variable acquisition time. Relationship with SNR. <i>Physics in Medicine and Biology</i> , 2014, 59, 6417-6430. | 3.0 | 25 |
| 97 | Radioimmunoconjugates for the Treatment of Cancer. <i>Seminars in Oncology</i> , 2014, 41, 613-622. | 2.2 | 65 |
| 98 | Laparoscopic Sentinel Lymph Node Versus Hyperextensive Pelvic Dissection for Staging Clinically Localized Prostate Carcinoma: A Prospective Study of 200 Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 753-758. | 5.0 | 26 |
| 99 | 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1501-1510. | 6.4 | 14 |
| 100 | Quality of Life is Modestly Improved in Older Patients with Mild Primary Hyperparathyroidism Postoperatively: Results of a Prospective Multicenter Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 3534-3540. | 1.5 | 30 |
| 101 | Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS</i> "RAF" Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 4251-4261. | 7.0 | 60 |
| 102 | Fractionated ⁹⁰ Y-britumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. <i>Journal of Clinical Oncology</i> , 2014, 32, 212-218. | 1.6 | 57 |
| 103 | Prognostic Value and Clinical Impact of 18FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy. <i>Frontiers in Medicine</i> , 2014, 1, 54. | 2.6 | 17 |
| 104 | Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. <i>EJNMMI Research</i> , 2013, 3, 11. | 2.5 | 67 |
| 105 | Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1373-1376. | 6.4 | 6 |
| 106 | <i>BCR</i> "ABL" 1 molecular remission after ⁹⁰ Y "pratumab tetraxetan radioimmunotherapy in <i>CD</i> 22+ <i>P</i> h+ <i>B</i> "ALL": proof of principle. <i>European Journal of Haematology</i> , 2013, 91, 552-556. | 2.2 | 19 |
| 107 | Medullary Thyroid Carcinoma. , 2013, , 155-163. | | 0 |
| 108 | La place de la TEP au FDG dans lâ€™Ã©valuation des lymphomes en 2012. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 164-174. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | La TEP au FDG dans lâ€™Ã©valuation du myÃ©lome en 2012. Diagnostic and Interventional Imaging, 2013, 94, 190-195. | 0.0 | 0 |
| 110 | Clinical NECR in 18F-FDG PET scans: Optimization of patient specific activity and variable acquisition time. Relationship with SNR. , 2013, , . | | 0 |
| 111 | Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients. Immunotherapy, 2013, 5, 1283-1286. | 2.0 | 3 |
| 112 | Radioimmunotherapy of B-cell non-Hodgkinâ€™s lymphoma. Frontiers in Oncology, 2013, 3, 177. | 2.8 | 30 |
| 113 | Improvement of Radioimmunotherapy Using Pretargeting. Frontiers in Oncology, 2013, 3, 159. | 2.8 | 30 |
| 114 | ²¹³ Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma. Journal of Nuclear Medicine, 2013, 54, 1597-1604. | 5.0 | 65 |
| 115 | ¹⁸ F-fluorodeoxyglucose positron emission tomographyâ€‘computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: A prospective study. International Journal of Urology, 2013, 20, 788-796. | 1.0 | 43 |
| 116 | Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma. Nuclear Medicine Communications, 2013, 34, 674-681. | 1.1 | 18 |
| 117 | Radionuclide Metabolic Therapy. , 2013, , . | | 0 |
| 118 | Medullary Thyroid Carcinoma. Medical Radiology, 2012, , 315-321. | 0.1 | 0 |
| 119 | Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 4794-4805. | 7.0 | 65 |
| 120 | First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clinical Cancer Research, 2012, 18, 4806-4819. | 7.0 | 136 |
| 121 | Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. Journal of Nuclear Medicine, 2012, 53, 1185-1192. | 5.0 | 74 |
| 122 | Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by ¹⁸ F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials. Journal of Nuclear Medicine, 2012, 53, 1836-1846. | 5.0 | 22 |
| 123 | Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time. Journal of Clinical Oncology, 2012, 30, 2165-2165. | 1.6 | 8 |
| 124 | Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. Medical Radiology, 2012, , 551-556. | 0.1 | 1 |
| 125 | ModÃ©lisation du taux de comptage en TEP Ã© partir de donnÃ©es cliniquesÃ©: une voie robuste pour lâ€™optimisation des paramÃ©tres dâ€™acquisitionÃ©?. Medecine Nucleaire, 2012, 36, 209-214. | 0.2 | 0 |
| 126 | Les outils de mÃ©decine nuclÃ©aire pour le dÃ©veloppement de la mÃ©decine personnalisÃ©e dans le cancer du sein. Medecine Nucleaire, 2012, 36, 233-236. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Les cancers gynÄ©cologiquesÄ: une prise en charge multidisciplinaire Ä propos de trois cas cliniques. Medecine Nucleaire, 2012, 36, 462-468. | 0.2 | 0 |
| 128 | Imagerie TEP/TDM FDG du pelvis de la femme. Medecine Nucleaire, 2012, 36, 445-450. | 0.2 | 0 |
| 129 | Radiolabeled Antibodies for Cancer Imaging and Therapy. Methods in Molecular Biology, 2012, 907, 681-697. | 0.9 | 61 |
| 130 | Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). Tumor Biology, 2012, 33, 601-606. | 1.8 | 14 |
| 131 | Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumor Biology, 2012, 33, 679-688. | 1.8 | 48 |
| 132 | Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 291-299. | 6.4 | 19 |
| 133 | Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. Blood, 2012, 120, 906-906. | 1.4 | 5 |
| 134 | Ätude de faisabilitÄ© du ganglion sentinelle dans le cancer de la prostate par cÄ©lioscopieÄ: premiers rÄ©sultats. Medecine Nucleaire, 2011, 35, 461-469. | 0.2 | 0 |
| 135 | Consolidation par 90Y-epratuzumab en fractionnÄ© dans le lymphome B diffus Ä grandes cellulesÄ: rÄ©sultats prÄ©liminaires dÄ©tude de phase II. Medecine Nucleaire, 2011, 35, 478-486. | 0.2 | 0 |
| 136 | Ävaluation de la rÄ©ponse thÄ©rapeutique par tomographie par Ä©mission de positons (TEP) au 18fluoro-dÄ©soxyglucose (FDG) en oncologie-hÄ©matologie. Medecine Nucleaire, 2011, 35, 600-607. | 0.2 | 5 |
| 137 | IntÄ©rÄ©t des traceurs de lâ©TMhypoxie en radiothÄ©rapie. Medecine Nucleaire, 2011, 35, 621-624. | 0.2 | 0 |
| 138 | RadiothÄ©rapie vectorisÄ©eÄ: les nouvelles molÄ©cules. Medecine Nucleaire, 2011, 35, 613-616. | 0.2 | 1 |
| 139 | Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence. European Journal of Gastroenterology and Hepatology, 2011, 23, 275-281. | 1.6 | 27 |
| 140 | Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. EJNMMI Research, 2011, 1, 20. | 2.5 | 44 |
| 141 | FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1029-1036. | 6.4 | 51 |
| 142 | EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1393-1406. | 6.4 | 199 |
| 143 | Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplantation, 2011, 46, 393-399. | 2.4 | 24 |
| 144 | First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2011, 29, 3006-3006. | 1.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.. Journal of Clinical Oncology, 2011, 29, 3017-3017. | 1.6 | 7 |
| 146 | Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1270-1278. | 6.4 | 42 |
| 147 | Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1633-1642. | 6.4 | 76 |
| 148 | 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1669-1678. | 6.4 | 77 |
| 149 | Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer, 2010, 116, 1053-1058. | 4.1 | 25 |
| 150 | Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer, 2010, 116, 1093-1100. | 4.1 | 33 |
| 151 | Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. Cancer, 2010, 116, 1118-1125. | 4.1 | 19 |
| 152 | High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 3709-3716. | 1.6 | 106 |
| 153 | Comparative Toxicity and Efficacy of Combined Radioimmunotherapy and Antiangiogenic Therapy in Carcinoembryonic Antigen-Expressing Medullary Thyroid Cancer Xenograft. Journal of Nuclear Medicine, 2010, 51, 624-631. | 5.0 | 19 |
| 154 | Lâ€™immuno-TEP, une nouvelle approche dâ€™imagerie molâ€™culaire. Medecine Nucleaire, 2010, 34, 295-298. | 0.2 | 1 |
| 155 | Apport de la TEP/TDM au 18FDG dans la stadification initiale et lâ€™Ã©valuation prâ€™ocoe de la rÃ©ponse thÃ©rapeutique des rhabdomyosarcomes pÃ©diatriques. Medecine Nucleaire, 2010, 34, 655-663. | 0.2 | 2 |
| 156 | Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients. Blood, 2010, 116, 2875-2875. | 1.4 | 10 |
| 157 | Respective PROGNOSTIC Value of the International Harmonization PROJECT (IHP), Gallamini and London Criteria for Interim FDG PET-CT Performed AFTER 4 Courses of ABVD IN HODGKIN'S LYMPHOMA. Blood, 2010, 116, 3889-3889. | 1.4 | 1 |
| 158 | La place de la TEP au 18FDG dans lâ€™Ã©valuation des lymphomes. Hematologie, 2009, 15, 305-312. | 0.0 | 0 |
| 159 | Does ¹⁸ F-FDG PET/CT Improve the Detection of Posttreatment Recurrence of Head and Neck Squamous Cell Carcinoma in Patients Negative for Disease on Clinical Follow-up?. Journal of Nuclear Medicine, 2009, 50, 24-29. | 5.0 | 231 |
| 160 | Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1813-1821. | 6.4 | 111 |
| 161 | La radio-immunothÃ©rapie. Medecine Nucleaire, 2009, 33, 148-151. | 0.2 | 0 |
| 162 | IntÃ©rÃ©t de la tomographie par Ã©mission de positons (TEP) au 18FDG dans le suivi des patients traitÃ©s pour carcinome Ã©pidermoÃ© des voies aÃ©rodigestives supÃ©rieures (VADS) en Ã©mission clinique. Medecine Nucleaire, 2009, 33, 193-200. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Les essais cliniques en médecine nucléaire: État et perspectives. <i>Medecine Nucleaire</i> , 2009, 33, 296-304. | 0.2 | 1 |
| 164 | Current Status and Perspectives in Peptide Receptor Radiation Therapy. <i>Current Pharmaceutical Design</i> , 2009, 15, 2453-2462. | 1.9 | 26 |
| 165 | Pretargeted Radioimmunotherapy in the Treatment of Metastatic Medullary Thyroid Cancer. <i>Current Oncology</i> , 2009, 16, 3-8. | 2.2 | 10 |
| 166 | ^{99m} Tc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 637-643. | 6.4 | 44 |
| 167 | Consolidation radioimmunotherapy of follicular lymphoma: a step towards cure?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1236-1239. | 6.4 | 8 |
| 168 | La radio-immunothérapie en clinique. <i>Medecine Nucleaire</i> , 2008, 32, 254-257. | 0.2 | 1 |
| 169 | Review: What Can Be Expected from Nuclear Medicine Tomorrow?. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 483-504. | 1.0 | 16 |
| 170 | Evaluation of response to fractionated radioimmunotherapy with ⁹⁰ Y-estratumab in non-Hodgkin's lymphoma by ¹⁸ F-fluorodeoxyglucose positron emission tomography. <i>Haematologica</i> , 2008, 93, 390-397. | 3.5 | 45 |
| 171 | Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. <i>Haematologica</i> , 2008, 93, 471-472. | 3.5 | 130 |
| 172 | ¹⁸ F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. <i>Haematologica</i> , 2008, 93, 128-131. | 3.5 | 28 |
| 173 | Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, estratumab: Results at high cumulative doses of ⁹⁰ Y. <i>Journal of Clinical Oncology</i> , 2008, 26, 8502-8502. | 1.6 | 7 |
| 174 | Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4590-4597. | 3.6 | 89 |
| 175 | Does ¹⁸ F-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up?. <i>Head and Neck</i> , 2007, 29, 1115-1120. | 2.0 | 51 |
| 176 | A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET. <i>Gynecologic Oncology</i> , 2007, 105, 545-547. | 1.4 | 9 |
| 177 | Therapeutic impact of ¹⁸ F-FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. <i>Surgery</i> , 2007, 142, 952-958. | 1.9 | 63 |
| 178 | Prospective comparison of two gamma probes for intraoperative detection of ¹⁸ F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1556-1562. | 6.4 | 27 |
| 179 | Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richter's Syndrome.. <i>Blood</i> , 2007, 110, 1390-1390. | 1.4 | 0 |
| 180 | Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 1705-1711. | 1.6 | 231 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and ¹³¹ I-labeled bivalent hapten in a phase I optimization clinical trial. <i>Journal of Nuclear Medicine</i> , 2006, 47, 247-55. | 5.0 | 88 |
| 182 | Feasibility and benefit of fluorine ¹⁸ F-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases. <i>Surgery</i> , 2005, 138, 1176-1182. | 1.9 | 45 |
| 183 | High Frequency of Bone/Bone Marrow Involvement in Advanced Medullary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 779-788. | 3.6 | 79 |
| 184 | Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6077-6084. | 3.6 | 361 |
| 185 | Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine- ¹³¹ I-labeled hapten in a phase I radioimmunotherapy trial. <i>Clinical Cancer Research</i> , 2003, 9, 3973S-81S. | 7.0 | 37 |
| 186 | Radioimmunotherapy of non-Hodgkin's lymphoma with ⁹⁰ Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?. <i>Journal of Nuclear Medicine</i> , 2003, 44, 2000-18. | 5.0 | 62 |
| 187 | Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine- ¹³¹ I and bismuth- ²¹³ Bi on multiple myeloma. <i>Cancer</i> , 2002, 94, 1202-1209. | 4.1 | 60 |
| 188 | Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 267-74. | 4.1 | 31 |
| 189 | Variation in phytoplankton composition and limnological features in a water-water ecotone of the Lower Paraná Basin (Argentina). <i>Freshwater Biology</i> , 2001, 46, 63-74. | 2.4 | 13 |
| 190 | Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1487-1493. | 2.1 | 107 |
| 191 | Nuclear Medicine Applications for Neuroendocrine Tumors. <i>World Journal of Surgery</i> , 2000, 24, 1285-1289. | 1.6 | 41 |
| 192 | Pretargeting with the Affinity Enhancement System for Radioimmunotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1999, 14, 153-166. | 1.0 | 65 |